Tokyo Tape
Sign in
← Nipro

Quarterly report · Q3

8086.TEDINET S100STZ2
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
MetricValuePeriodScopeSource row
Revenue¥439.1bn2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥545.2bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥406.3bn2022-04-01 → 2022-12-31Cons.Net sales
Operating income¥22.4bn2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥13.2bn2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income¥20.0bn2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥15.3bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥13.8bn2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥22.1bn2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥14.7bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥12.6bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.6bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥7.0bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥13.5bn2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥8.1bn2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥1.11Tat 2023-12-31Cons.Assets
Total assets¥1.03Tat 2023-03-31Cons.Assets
Total assets¥1.05Tat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥831.3bnat 2023-12-31Cons.Liabilities
Total liabilities¥785.2bnat 2023-03-31Cons.Liabilities
Net assets / equity¥280.6bnat 2023-12-31Cons.Net assets
Net assets / equity¥242.2bnat 2023-03-31Cons.Net assets
Net assets / equity¥240.2bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥79.4bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥89.7bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥77.442023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥16.552023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥28.052022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥42.692022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥4.352022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥68.612023-04-01 → 2023-12-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥24.852022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥37.822022-04-01 → 2022-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio21.9%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio20.1%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio21.3%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-12-31¥3.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-12-31¥642m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-12-31¥3.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-12-31−¥200m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥54.6bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥54.6bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥19.8bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentrevenue2023-04-01 → 2023-12-31¥345.3bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2023-04-01 → 2023-12-31¥340.3bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥5.0bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2023-04-01 → 2023-12-31¥35.4bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentrevenue2023-04-01 → 2023-12-31¥96.0bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentrevenue external2023-04-01 → 2023-12-31¥54.2bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥41.8bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentsegment profit2023-04-01 → 2023-12-31¥5.3bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentrevenue2023-04-01 → 2023-12-31¥48.6bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentrevenue external2023-04-01 → 2023-12-31¥43.9bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥4.7bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentsegment profit2023-04-01 → 2023-12-31¥1.6bn
—segment totalrevenue2023-04-01 → 2023-12-31¥490.0bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥438.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-12-31¥51.5bn
—segment totalsegment profit2023-04-01 → 2023-12-31¥42.3bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-12-31¥493.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-12-31¥439.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-12-31¥54.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-12-31¥42.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-12-31¥3.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-12-31¥530m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-12-31¥2.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-12-31¥166m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥28.6bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥28.6bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥22.5bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentrevenue2022-04-01 → 2022-12-31¥318.8bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2022-04-01 → 2022-12-31¥314.2bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥4.6bn
jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2022-04-01 → 2022-12-31¥30.8bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentrevenue2022-04-01 → 2022-12-31¥70.3bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentrevenue external2022-04-01 → 2022-12-31¥53.6bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥16.8bn
jpcrp040300-q3r_E02688-000Medicine Relatedreportable segmentsegment profit2022-04-01 → 2022-12-31¥2.2bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentrevenue2022-04-01 → 2022-12-31¥42.6bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentrevenue external2022-04-01 → 2022-12-31¥38.0bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥4.6bn
jpcrp040300-q3r_E02688-000Pharma Packagingreportable segmentsegment profit2022-04-01 → 2022-12-31¥2.5bn
—segment totalrevenue2022-04-01 → 2022-12-31¥431.7bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥405.8bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥25.9bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥35.5bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥434.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥406.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥28.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥35.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 445
ItemContextValueUnit
Net assetsCurrentQuarterInstant280628000000JPY
Liabilities and net assetsPrior1YearInstant1027399000000JPY
Liabilities and net assetsCurrentQuarterInstant1111899000000JPY
Net salesPrior1YTDDuration406301000000JPY
Net salesCurrentYTDDuration439135000000JPY
Cost of salesPrior1YTDDuration284355000000JPY
Cost of salesCurrentYTDDuration307063000000JPY
Gross profitPrior1YTDDuration121946000000JPY
Gross profitCurrentYTDDuration132071000000JPY
Selling general and administrative expensesPrior1YTDDuration108766000000JPY
Selling general and administrative expensesCurrentYTDDuration109709000000JPY
Operating incomePrior1YTDDuration13179000000JPY
Operating incomeCurrentYTDDuration22362000000JPY
Interest income noiPrior1YTDDuration746000000JPY
Interest income noiCurrentYTDDuration1148000000JPY
Dividends income noiPrior1YTDDuration789000000JPY
Dividends income noiCurrentYTDDuration535000000JPY
Foreign exchange gains noiPrior1YTDDuration3075000000JPY
Foreign exchange gains noiCurrentYTDDuration1311000000JPY
Other noiPrior1YTDDuration1860000000JPY
Other noiCurrentYTDDuration2179000000JPY
Non operating incomePrior1YTDDuration6471000000JPY
Non operating incomeCurrentYTDDuration5175000000JPY
Interest expenses noePrior1YTDDuration3163000000JPY
Interest expenses noeCurrentYTDDuration4650000000JPY
Equity in losses of affiliates noePrior1YTDDuration1044000000JPY
Equity in losses of affiliates noeCurrentYTDDuration1425000000JPY
Other noePrior1YTDDuration1671000000JPY
Other noeCurrentYTDDuration1451000000JPY
Non operating expensesPrior1YTDDuration5879000000JPY
Non operating expensesCurrentYTDDuration7527000000JPY
Ordinary incomePrior1YTDDuration13772000000JPY
Ordinary incomeCurrentYTDDuration20010000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration2322000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration841000000JPY
Gain on sales of investment securities eiPrior1YTDDuration501000000JPY
Gain on sales of investment securities eiCurrentYTDDuration3682000000JPY
State subsidy eiPrior1YTDDuration785000000JPY
State subsidy eiCurrentYTDDuration367000000JPY
Other eiPrior1YTDDuration124000000JPY
Other eiCurrentYTDDuration273000000JPY
Extraordinary incomePrior1YTDDuration3734000000JPY
Extraordinary incomeCurrentYTDDuration5164000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration438000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration521000000JPY
Loss on reduction of noncurrent assets elPrior1YTDDuration785000000JPY
Loss on reduction of noncurrent assets elCurrentYTDDuration161000000JPY
Loss on sale of investment in affiliated companies elPrior1YTDDuration－JPY
Loss on sale of investment in affiliated companies elCurrentYTDDuration1646000000JPY
Other elPrior1YTDDuration1558000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass